BlossomHill Therapeutics (NASDAQ:BLSM) Stock Moved Down to Sell by Wall Street Zen

Wall Street Zen lowered shares of BlossomHill Therapeutics (NASDAQ:BLSM) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other research firms also recently weighed in on BLSM. Zacks Research raised shares of BlossomHill Therapeutics to a “hold” rating in a research report on Wednesday, September 2nd. Leerink Partners lifted their target price on BlossomHill Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, September 21st. Guggenheim upped their target price on BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a report on Monday, September 21st. Lifesci Capital initiated coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $32.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of BlossomHill Therapeutics in a research report on Wednesday, September 30th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $35.00.

BlossomHill Therapeutics Trading Down 5.5%

NASDAQ:BLSM traded down $0.82 on Friday, reaching $14.02. The stock had a trading volume of 222,586 shares, compared to its average volume of 169,753. The stock’s 50-day moving average price is $18.01. The company has a market cap of $445.56 million and a PE ratio of -1.60. BlossomHill Therapeutics has a 12-month low of $11.02 and a 12-month high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM) last announced its earnings results on Thursday, November 12th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.36). As a group, equities analysts predict that BlossomHill Therapeutics will post -5.54 EPS for the current fiscal year.

About BlossomHill Therapeutics

BlossomHill Therapeutics is a biotechnology company focused on developing medicines for cancer. Its research has centered on targeted small-molecule treatments designed to address cancer-related genetic changes. The company’s pipeline has included BH-306, an investigational inhibitor of mutant IDH1 being developed for cancers associated with that mutation. The program is in development and is not a marketed treatment. Publicly available information about the company’s leadership and geographic operations is limited.